Editing Daiichi Sankyo Company, Limited (section)

== Leadership ==
[[File:Manabe.jpg|thumb|189x189px|Sunao Manabe - Representative Director, Executive Chairperson & CEO]][[File:Okuzawa-san 2021.jpg|thumb|189x189px|Hiroyuko Okuzawa - Representative Director, President & COO]][[File:Hirashima-san 2021.jpg|thumb|187x187px|Shoji Hirashima - Representative Director, SEO, Head of Japan Business Unit]][[File:Ohtsuki-san 2021.jpg|thumb|184x184px|Masahiko Ohtsuki - Director, SEO, Head of Global DX CDXO]][[File:Fukuoka-san.jpg|thumb|181x181px|Takashi Fukuoka - Director, SEO, Head of Global Corporate Strategy]][[File:Kama-san 2021.jpg|thumb|176x176px|Kazuaki Kama - Outside Director (Independent Director), Chairperson of the Board]][[File:Nohara-san 2021.jpg|thumb|177x177px|Sawako Nohara - Outside Director (Independent Director), Chairperson of the Compensation Committee]][[File:Komatsu-san 2206.jpg|thumb|169x169px|Yasuhiro Komatsu - Outside Director (Independent Director)]]
=== Board Of Directors: ===

'''Sunao Manabe''' is the '''Representative Director Executive, Chairperson & CEO''' of Daiichi Sankyo, with a Masters in Medical Science (Experimental Pathology) from the University of Tsukukba and a PhD from the University of Tokyo, he has been with the company since 1978.


'''Hiroyuki Okuzawa''' is the '''Representative Director, President & COO''' of Daiichi Sankyo since April 1, 2023. The reason for which being to ensure that the company with achieve the 5-Year Business Plan via maximizing the value of the 3ADCs, active R&D, supply chain and oncology business investment. He has been with the company since 1986


'''Shoji Hirashima''' is a '''Representative Director, Senior Executive Officer, and Head of Japan Business Unit'''. He studied Business and Management at UC Berkeley and has a PhD in Molecular Biology, Biochemistry from the University of Tokyo. He has a considerable background in R&D and Business Development, leading the R&D division from 2010 - 2017 and the Business Development and Licencing Department from 2018 - 2020.


'''Masahiko Ohtsuki''' is a '''Director, Senior Executive Officer and the Head of Global DX CDXO'''. He has has a PhD in Pharmaceutical Science from the University of Tokyo and has been with company since 1987.


'''Takashi Fukuoka''' is a '''Director, Senior Executive Officer, and the Head of Global Corporate Strategy''' and has been with the company since 1987. He has fulfilled a variety of managerial positions, being promoted to Vice President of Venture Science Laboratories in 2013, Corporate Officer in 2019, and Executive Officer in 2022.


'''Kazuaki Kama''' is an '''Outside Director (Independent Director) and Chairperson of the Board''', he has been a Senior Advisor of IHI Corporation since Apr. 2020 and an Outside Director to Daiichi Sankyo since Jun. 2019.


'''Sawako Nohara''' is an '''Outside Director''' (Independent Director) and Chairperson of the Compensation Committee, and has been since Jun. 2019. To date she is an Outside Director of Keikyu Corporation since Jun. 2021 and and Outside Director of Resona Holdings, Inc. since Jun. 2022. Prior to these roles she has been a Director and President of a variety of companies, including NEC Corporation, NKSJ Holdings, Inc., JAPAN POST BANK Co., and more, providing insight from a varied background.


'''Yasuhiro Komatsu''' is an '''Outside Director''' and has been since Jun. 2022. He has been a Director and Chairman at a diverse array of Hospitals and Healthcare Departments. Assisting the company with a key strategic pillar, creating shared value with stakeholders, providing insight on creating a "Patient Centric Mindset"<ref>https://www.daiichisankyo.com/about_us/mission-strength/leadership/</ref>